Macular Hole Progression following Ocriplasmin Intravitreal Injection

Edward J. Casswell, Guillermo Fernández‐Sanz, Danny Mitry, Sheila Luk, Rahila Zakir

Case Reports in Ophthalmological Medicine · 2014 · 10 citations · 3 references

DOIFull text

Open access

Concepts

Abstract

Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.

References

3